Aminocaproic acid

Generic Medicine Info
Indications and Dosage
Treatment and prophylaxis of haemorrhage
Adult: For bleeding due to hyperfibrinolysis: As 2% soln: Initially, 4-5 g over 1 hr, followed by continuous infusion at a rate of 1 g/hr for up to 8 hr or until bleeding has been controlled. Max: 24 g daily.

Treatment and prophylaxis of haemorrhage
Adult: For bleeding due to hyperfibrinolysis: Initially, 4-5 g, followed by 1-1.25 g hrly for up to 8 hr or until bleeding has been controlled. Max: 24 g daily.

Patients with haemophilia undergoing dental extraction
Adult: 50-100 mg/kg (up to 6 g) 4-6 hrly, started before the procedure up to a total of 7-10 days. Max: 24 hr daily.
Renal Impairment
Reduce dose if necessary.
May be taken with or without food. May be taken w/ meals to prevent GI upset.
Dilute w/ NaCl 0.9%, dextrose 5%, or Ringer’s inj.
Active intravascular clotting process, disseminated intravascular coagulation (w/o heparin). Concomitant use w/ factor IX complex and anti-inhibitor coagulant complex.
Special Precautions
Patient w/ cardiac disease, haematuria of upper urinary tract, uraemia. Admin by rapid IV inj of undiluted soln. Hepatic and renal impairment. Pregnancy and lactation.
Adverse Reactions
Headache, oedema, tinnitus, nasal and conjunctival congestion, malaise; anaphylaxis, rash; thrombosis; hypotension, bradycardia, peripheral ischaemia; abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, coagulation disorder, leucopenia, thrombocytopenia; increased CPK, muscle weakness, myalgia, myopathy, myositis, rhabdomyolysis; increase BUN, confusion, convulsions, delirium, dizziness, hallucinations, intracranial HTN, stroke, syncope, dyspnoea, pulmonary embolism, pruritus; decreased vision, watery eyes, cardiac and hepatic damage, renal failure.
IV/Parenteral/PO: C
Monitoring Parameters
Monitor creatine phosphokinase (CPK) for signs of muscle damage esp in patients receiving long-term therapy. Monitor for fibrinogen, fibrin split products, BUN, and creatinine.
Symptoms: Transient hypotension, severe acute renal failure, seizures. Management: Haemodialysis or peritoneal dialysis may be beneficial.
Drug Interactions
Enhanced thrombogenic effect w/ oral tretinoin. May increase risk of thrombosis w/ fibrinogen concentrate.
Potentially Fatal: May enhance risk of thrombosis w/ factor IX complex and anti-inhibitor coagulant complex.
Lab Interference
May cause prolongation of template bleeding time at dosages >24 g daily.
Description: Aminocaproic acid is an antifibrinolytic used similarly to tranexamic acid. It inhibits fibrinolysis by competitively binding to plasminogen, blocking its binding to fibrin and the subsequent conversion to plasmin.
Onset: Approx 1-72 hr.
Absorption: Rapidly and completely absorbed from the GI tract. Bioavailability: 100% (oral). Time to peak plasma concentration: W/in 2 hr (oral).
Distribution: Widely distributed through intravascular and extravascular compartments. Volume of distribution: 23 L (oral); 30 L (IV).
Metabolism: Metabolised minimally in the liver.
Excretion: Via urine (65% as unchanged drug, approx 11% as metabolites). Elimination half-life: 1-2 hr.
Chemical Structure

Chemical Structure Image
Aminocaproic acid

Source: National Center for Biotechnology Information. PubChem Database. Aminocaproic acid, CID=564, (accessed on Jan. 20, 2020)

Store between 15-30°C. Do not freeze.
MIMS Class
ATC Classification
B02AA01 - aminocaproic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
Aminocaproic Acid Injection, Solution (American Regent, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/09/2016.

Aminocaproic Acid Solution and Tablet (Clover Pharmaceuticals Corp.). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/09/2016.

Anon. Aminocaproic Acid. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 08/09/2016.

Buckingham R (ed). Aminocaproic Acid. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/09/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Aminocaproic Acid. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 08/09/2016.

Disclaimer: This information is independently developed by MIMS based on Aminocaproic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in